Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial Of Fulvestrant (Faslodex (Registered)). With Or Without Pd-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Goserelin
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PALOMA-3
- Sponsors Pfizer
- 01 Feb 2024 Results appling a tumor regression-growth model to radiographic measurement data from 393 women with MBC enrolled in this study examining efficacy of palbociclib in disease that had progressed on previous endocrine therapy , published in the Breast Cancer Research and Treatment
- 12 Jan 2023 Results published in the Breast Cancer Research
- 10 Dec 2022 Results exploring the prognostic and predictive role of RBsig and CCNE1/RB1 in PALOMA-2 and PALOMA-3, presented at the 45th Annual San Antonio Breast Cancer Symposium